Trial Profile
A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates for CYP1A2 and CYP2D6 in Male Subjects With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Caffeine; Dextromethorphan
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 27 Aug 2014 New trial record